Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial

Ben J. Slotman*, Corinne Faivre-Finn, Harm van Tinteren, Astrid Keijserd, John Praag, Joost Knegjens, Matthew Hatton, Iris van Dam, Annija van der Leest, Bart Reymen, Jos Stigt, Kate Haslett, Devashish Tripathi, Egbert F. Smit, Suresh Senan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)150-153
Number of pages4
JournalLung Cancer
Volume108
DOIs
Publication statusPublished - Jun 2017

Keywords

  • Thoracic radiotherapy
  • Extensive stage
  • Small cell lung cancer
  • Metastases
  • CELL LUNG-CANCER
  • PROPHYLACTIC CRANIAL IRRADIATION

Cite this

Slotman, B. J., Faivre-Finn, C., van Tinteren, H., Keijserd, A., Praag, J., Knegjens, J., Hatton, M., van Dam, I., van der Leest, A., Reymen, B., Stigt, J., Haslett, K., Tripathi, D., Smit, E. F., & Senan, S. (2017). Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer, 108, 150-153. https://doi.org/10.1016/j.lungcan.2017.03.007